Literature DB >> 24519062

Mutations and Krüppel-like factor 6 (KLF6) expression levels in breast cancer.

Filiz Ozdemir1, Mehtap Koksal, Vahit Ozmen, Ibrahim Aydin, Nur Buyru.   

Abstract

The transcription factor KLF6 gene has been identified as a tumor suppressor because of its inactivation in several types of cancers by different mechanisms. However, there are no data in the literature investigating the KLF6 mutation rate and expression levels in breast cancer. Therefore, the present study was conducted in order to investigate whether genetic alterations of KLF6 in association with the KLF6 mRNA expression levels may play a role in breast carcinogenesis. For this purpose, we analyzed alterations of the KLF6 gene by direct sequencing and the mRNA levels by reverse transcription-PCR (RT-PCR). In addition to four different non-coding alterations, one missense and two silent alterations were identified in the coding sequence. Reduced KLF6 expression was observed in 41 (83.67 %) of the 49 breast cancer tumors. These findings suggest that the mutation profile of the KLF6 gene in breast tumors is similar to other cancer types. However, these mutations do not exert any effect on the gene expression rate. Downregulation of KLF6 during the progression of breast cancer is independent of the mutations and occurs by a different mechanism.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24519062     DOI: 10.1007/s13277-014-1678-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  43 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  KLF6, a candidate tumor suppressor gene mutated in prostate cancer.

Authors:  G Narla; K E Heath; H L Reeves; D Li; L E Giono; A C Kimmelman; M J Glucksman; J Narla; F J Eng; A M Chan; A C Ferrari; J A Martignetti; S L Friedman
Journal:  Science       Date:  2001-12-21       Impact factor: 47.728

3.  Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.

Authors:  Goutham Narla; Analisa DiFeo; Shen Yao; Asoka Banno; Eldad Hod; Helen L Reeves; Rui F Qiao; Olga Camacho-Vanegas; Alice Levine; Alexander Kirschenbaum; Andrew M Chan; Scott L Friedman; John A Martignetti
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

4.  Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination.

Authors:  Analisa DiFeo; Goutham Narla; Jennifer Hirshfeld; Olga Camacho-Vanegas; Jyothsna Narla; Stephen L Rose; Tamara Kalir; Shen Yao; Alice Levine; Michael J Birrer; Tomas Bonome; Scott L Friedman; Richard E Buller; John A Martignetti
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

5.  A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk.

Authors:  Goutham Narla; Analisa Difeo; Helen L Reeves; Daniel J Schaid; Jennifer Hirshfeld; Eldad Hod; Amanda Katz; William B Isaacs; Scott Hebbring; Akira Komiya; Shannon K McDonnell; Kathleen E Wiley; Steven J Jacobsen; Sarah D Isaacs; Patrick C Walsh; S Lilly Zheng; Bao-Li Chang; Danielle M Friedrichsen; Janet L Stanford; Elaine A Ostrander; Arul M Chinnaiyan; Mark A Rubin; Jianfeng Xu; Stephen N Thibodeau; Scott L Friedman; John A Martignetti
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

6.  The Krüppel-like transcription factor 6 gene in sporadic pituitary tumours.

Authors:  V V Vax; M Gueorguiev; I I Dedov; A B Grossman; M Korbonits
Journal:  Endocr Relat Cancer       Date:  2003-09       Impact factor: 5.678

7.  Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1.

Authors:  Sharon Benzeno; Goutham Narla; Jorge Allina; George Z Cheng; Helen L Reeves; Michaela S Banck; Joseph A Odin; J Alan Diehl; Doris Germain; Scott L Friedman
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

8.  Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.

Authors:  Steven Yea; Goutham Narla; Xiao Zhao; Rakhi Garg; Sigal Tal-Kremer; Eldad Hod; Augusto Villanueva; Johnny Loke; Mirko Tarocchi; Kunihara Akita; Senji Shirasawa; Takehiko Sasazuki; John A Martignetti; Josep M Llovet; Scott L Friedman
Journal:  Gastroenterology       Date:  2008-02-13       Impact factor: 22.682

9.  Functional role of the KLF6 tumour suppressor gene in gastric cancer.

Authors:  Jaya Sangodkar; Jiayan Shi; Analisa DiFeo; Rachel Schwartz; Romina Bromberg; Aisha Choudhri; Kim McClinch; Raheleh Hatami; Elias Scheer; Sigal Kremer-Tal; John A Martignetti; Alex Hui; W K Leung; Scott L Friedman; Goutham Narla
Journal:  Eur J Cancer       Date:  2008-12-26       Impact factor: 9.162

10.  [Mutation analysis of KLF6 gene in human nasopharyngeal carcinomas].

Authors:  Han-kui Chen; Xiao-qiong Liu; Jie Lin; Tian-yu Chen; Qi-sheng Feng; Yi-xin Zeng
Journal:  Ai Zheng       Date:  2002-10
View more
  11 in total

1.  Identification of miRNAs that specifically target tumor suppressive KLF6-FL rather than oncogenic KLF6-SV1 isoform.

Authors:  Wei-Cheng Liang; Yan Wang; Li-Jia Xiao; Yu-Bing Wang; Wei-Ming Fu; Wei-Mao Wang; Hui-Qing Jiang; Wei Qi; David Chi-Cheong Wan; Jin-Fang Zhang; Mary Miu-Yee Waye
Journal:  RNA Biol       Date:  2014-06-12       Impact factor: 4.652

2.  Kruppel-like factor 6 suppresses growth and invasion of hepatocellular carcinoma cells in vitro and in vivo.

Authors:  Pei-Hao Wen; Dong-Yu Wang; Jia-Kai Zhang; Zhi-Hui Wang; Jie Pan; Xiao-Yi Shi; Han Yang; Shui-Jun Zhang; Wen-Zhi Guo
Journal:  Int J Immunopathol Pharmacol       Date:  2016-08-10       Impact factor: 3.219

3.  Krüppel like factor 6 splice variant 1 (KLF6-SV1) overexpression recruits macrophages to participate in lung cancer metastasis by up-regulating TWIST1.

Authors:  Jian Wang; Xiao Wang; Yawei Wang; Shuguang Li; Xiuwen Wang
Journal:  Cancer Biol Ther       Date:  2018-12-27       Impact factor: 4.742

4.  Overexpression of the Oncogenic Variant (KLF6-SV1) in Young NPC Patients and Correlation with Lack of E-Cadherin.

Authors:  Saoussen Debouki-Joudi; Sonia Mhirsi; Nehla Mokni-Baizig; Nihel Ammous-Boukhris; Hayet Mhamdi; Said Gritli; Raja Mokdad Gargouri; Mohamed Nejib Marzouki
Journal:  Anal Cell Pathol (Amst)       Date:  2018-04-19       Impact factor: 2.916

Review 5.  Aberrant alternative splicing in breast cancer.

Authors:  Quan Yang; Jinyao Zhao; Wenjing Zhang; Dan Chen; Yang Wang
Journal:  J Mol Cell Biol       Date:  2019-10-25       Impact factor: 6.216

6.  Identification of miRNA Master Regulators in Breast Cancer.

Authors:  Antonio Daniel Martinez-Gutierrez; David Cantú de León; Oliver Millan-Catalan; Jossimar Coronel-Hernandez; Alma D Campos-Parra; Fany Porras-Reyes; Angelica Exayana-Alderete; César López-Camarillo; Nadia J Jacobo-Herrera; Rosalio Ramos-Payan; Carlos Pérez-Plasencia
Journal:  Cells       Date:  2020-07-03       Impact factor: 6.600

7.  CTCF and EGR1 suppress breast cancer cell migration through transcriptional control of Nm23-H1.

Authors:  Ka Ming Wong; Jiaxing Song; Yung H Wong
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

8.  The Growth of SGC-7901 Tumor Xenografts Was Suppressed by Chinese Bayberry Anthocyanin Extract through Upregulating KLF6 Gene Expression.

Authors:  Yue Wang; Xia-Nan Zhang; Wen-Hua Xie; Yi-Xiong Zheng; Jin-Ping Cao; Pei-Rang Cao; Qing-Jun Chen; Xian Li; Chong-de Sun
Journal:  Nutrients       Date:  2016-09-27       Impact factor: 5.717

Review 9.  A summary of relationships between alternative splicing and breast cancer.

Authors:  Zhang Xiping; Wei Qingshan; Zhao Shuai; Yang Hongjian; Ding Xiaowen
Journal:  Oncotarget       Date:  2017-05-09

10.  Long noncoding RNA ZBED3-AS1 restrains breast cancer progression by targeting the microRNA-513a-5p/KLF6 axis.

Authors:  Aiqin Fu; Ze Yu; Enning Zhang; Jijie Song
Journal:  Thorac Cancer       Date:  2021-08-24       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.